Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Randomized Phase III Study of the Docetaxel and Gemcitabine Combination Versus Monotherapy With Gemcitabine as First-line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)
Brief Summary: This trial will compare the efficacy of the docetaxel and gemcitabine combination versus monotherapy with gemcitabine as first-line treatment in elderly patients with advanced NSCLC


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Gemcitabine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): 2
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Monotherapy (gemcitabine or vinorelbine) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Monotherapy (gemcitabine or vinorelbine); Assigned to Arm(s): A
C: Arm Label: IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: IMC-1121B (ramucirumab), Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin | Arm Label: Pemetrexed + Carboplatin (AUC 6) or Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin | Arm Label: IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: IMC-1121B (ramucirumab), Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5) | Arm Label: Gemcitabine + Carboplatin (AUC 5) or Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5) | Intervention Type: BIOLOGICAL; Name: IMC-1121B (ramucirumab); Assigned to Arm(s): IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Carboplatin (AUC 6); Assigned to Arm(s): IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin | Intervention Type: DRUG; Name: Carboplatin (AUC 5); Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin
D: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): N/A

Answer: A